Topical Use of Difinsa53™ to Prevent Radiation Dermatitis
NCT02534129 is a phase 1/2 interventional trial sponsored by ProTechSure Scientific, Inc.. As of 21 Nov 2026, it was terminated. It studies Aquaphor and Difinsa53 in Radiodermatitis. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2015 and a primary completion date of 31 Mar 2016.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02534129 |
| Status | Terminated |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | ProTechSure Scientific, Inc. |
| Enrollment | 13 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Radiodermatitis |
| Drugs | Aquaphor and Difinsa53 |
| Start | 31 Aug 2015 |
| Primary completion | 31 Mar 2016 |
| Study completion | 31 Mar 2016 |
| Last update posted | 6 Oct 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joshua Petit, MD
UC Health, Poudre Valley Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Poudre Valley Health System
Fort Collins
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02534129
Each answer restates registry values shown on this page.
What is NCT02534129?
NCT02534129 is a phase 1/2 interventional trial sponsored by ProTechSure Scientific, Inc.. It studies Aquaphor and Difinsa53 in Radiodermatitis.
Who leads NCT02534129?
The registry names Joshua Petit, MD (principal investigator, UC Health, Poudre Valley Hospital) as the overall official.
Where does NCT02534129 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02534129 study?
The registered drug and biological interventions are Aquaphor and Difinsa53.
When did NCT02534129 end?
The registry lists a primary completion date of 31 Mar 2016 and a study completion date of 31 Mar 2016. The sponsor last updated the record on 6 Oct 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.